Rivastigmine transdermal system 13.3 mg/24 h    (DrugBank: Rivastigmine)

3 diseases
告示番号疾患名(ページ内リンク)臨床試験数
5進行性核上性麻痺0
6パーキンソン病1
13多発性硬化症/視神経脊髄炎0

5. 進行性核上性麻痺 [臨床試験数:82,薬物数:107(DrugBank:36),標的遺伝子数:60,標的パスウェイ数:90
Searched query = "Progressive supranuclear palsy", "PSP"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: . Trials are sorted by Date_enrollment from most recent to oldest in the table.
0 / 82 trial found

6. パーキンソン病 [臨床試験数:2,123,薬物数:2,046(DrugBank:324),標的遺伝子数:183,標的パスウェイ数:198
Searched query = "Parkinson disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 2,123 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2018-003219-23-GB
(EUCTR)
28/06/201904/06/2019CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson’s Disease)CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson’s Disease): A phase 3 randomised double-blind placebo-controlled trial of rivastigmine to prevent falls in Parkinson’s disease - CHIEF-PD This trial will investigate the effectiveness of Rivastigmine on prevention of falls in patients with Parkinson's disease
MedDRA version: 21.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 10029205 - Nervous system disorders
MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: Rivastigmin Luye Transdermal Patches - 4.6mg/24h
Product Name: Rivastigmin Luye Transdermal Patches - 4.6mg/24h
Product Code: N/A
INN or Proposed INN: Rivastigmine
Other descriptive name: Ethylmethylcarbamic acid 3-[(1S)-1-(dimethylamino)ethyl]phenyl ester (**See other 2 names below)
Trade Name: Rivastigmine Luye Transdermal Patch- 9.5mg/24h
Product Name: Rivastigmine Luye Transdermal Patch- 9.5mg/24h
INN or Proposed INN: Rivastigmine
Other descriptive name: Ethylmethylcarbamic acid 3-[(1S)-1-(dimethylamino)ethyl]phenyl ester (**See other 2 names below)
Product Name: Rivastigmine transdermal system 13.3 mg/24 h
Product Code: RIV-TDS 13.3 mg/24 h
INN or Proposed INN: Rivastigmine
Other descriptive name: Ethylmethylcarbamic acid 3-[(1S)-1-(dimethylamino)ethyl]phenyl ester (**See other 2 names below)
University of BristolNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
600Phase 3United Kingdom

13. 多発性硬化症/視神経脊髄炎 [臨床試験数:3,050,薬物数:2,147(DrugBank:348),標的遺伝子数:244,標的パスウェイ数:228
Searched query = "Multiple sclerosis/Neuromyelitis optica", "Multiple sclerosis", "Neuromyelitis optica", "MS", "NMOSD", "Devic disease", "Balo concentric sclerosis", "Baló concentric sclerosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: . Trials are sorted by Date_enrollment from most recent to oldest in the table.
0 / 3,050 trial found